Jama neurology publishes phase 3 study results comparing ipx203 to immediate-release carbidopa/levodopa for parkinson's disease

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) today announced that jama neurology has published results from the rise-pd clinical study assessing the efficacy and safety of ipx203 versus optimized immediate-release carbidopa/levodopa (ir cd/ld) for the treatment of parkinson's disease (pd). the study met its primary and secondary endpoints finding that ipx203 provided more hours of “good on” time per day, less “off” time per day, and more “good on” time per dose.
AMRX Ratings Summary
AMRX Quant Ranking